BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has announced its CEO Lance Alstodt will participate in the Benzinga All-Access Show on April 15, 2025, at 10:50 a.m. Eastern time.
During the interview, the company plans to discuss their recent achievements in clinical and regulatory milestones, along with highlighting commercial opportunities. The session will be accessible via live webcast and will subsequently be archived in the Investors section of the company's website.
BioRestorative Therapies (NASDAQ:BRTX), un'azienda di medicina rigenerativa in fase clinica specializzata in terapie a base di cellule staminali, ha annunciato che il suo CEO Lance Alstodt parteciperà al Benzinga All-Access Show il 15 aprile 2025 alle 10:50 ora Eastern.
Durante l'intervista, l'azienda discuterà i recenti traguardi clinici e normativi raggiunti, evidenziando anche le opportunità commerciali. La sessione sarà accessibile tramite webcast in diretta e successivamente archiviata nella sezione Investitori del sito web aziendale.
BioRestorative Therapies (NASDAQ:BRTX), una empresa de medicina regenerativa en etapa clínica especializada en terapias basadas en células madre, ha anunciado que su CEO Lance Alstodt participará en el Benzinga All-Access Show el 15 de abril de 2025 a las 10:50 a.m. hora del Este.
Durante la entrevista, la compañía planea hablar sobre sus recientes logros en hitos clínicos y regulatorios, además de resaltar las oportunidades comerciales. La sesión estará disponible vía webcast en vivo y posteriormente se archivará en la sección de Inversores del sitio web de la empresa.
BioRestorative Therapies (NASDAQ:BRTX)는 줄기세포 기반 치료를 전문으로 하는 임상 단계 재생 의학 회사로, CEO Lance Alstodt가 2025년 4월 15일 동부 시간 오전 10시 50분에 열리는 Benzinga All-Access Show에 참여할 것이라고 발표했습니다.
인터뷰 동안 회사는 최근 임상 및 규제 성과와 상업적 기회에 대해 논의할 예정입니다. 이 세션은 라이브 웹캐스트로 제공되며 이후 회사 웹사이트 투자자 섹션에 아카이브될 예정입니다.
BioRestorative Therapies (NASDAQ:BRTX), une entreprise de médecine régénérative en phase clinique spécialisée dans les thérapies à base de cellules souches, a annoncé que son PDG Lance Alstodt participera au Benzinga All-Access Show le 15 avril 2025 à 10h50 heure de l'Est.
Lors de l'entretien, la société prévoit de discuter de ses récentes avancées cliniques et réglementaires, tout en mettant en avant les opportunités commerciales. La session sera accessible en webcast en direct puis archivée dans la section Investisseurs du site internet de l'entreprise.
BioRestorative Therapies (NASDAQ:BRTX), ein klinisch tätiges Unternehmen für regenerative Medizin, das sich auf stammzellbasierte Therapien spezialisiert hat, hat bekannt gegeben, dass sein CEO Lance Alstodt am Benzinga All-Access Show am 15. April 2025 um 10:50 Uhr Eastern Time teilnehmen wird.
Während des Interviews plant das Unternehmen, über seine jüngsten klinischen und regulatorischen Meilensteine zu sprechen und dabei kommerzielle Chancen hervorzuheben. Die Sitzung wird als Live-Webcast zugänglich sein und anschließend im Investor-Bereich der Unternehmenswebsite archiviert.
- None.
- None.
MELVILLE, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Tuesday, April 15, 2025, at 10:50 a.m. Eastern time.
Benzinga All-Access Show
Date: Tuesday, April 15, 2025
Time: 10:50 a.m. Eastern Time
Live Webcast: https://youtube.com/live/YVur35nB9nc?feature=share
The interview will also be archived on the Investors section of the Company's website.
About BioRestorative Therapies, Inc.
BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we have also recently begun offering BioCosmeceutical products:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.
• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com
FAQ
When is BioRestorative Therapies (BRTX) appearing on the Benzinga All-Access Show?
What topics will be discussed during BRTX's Benzinga All-Access presentation?
How can investors watch BRTX's Benzinga All-Access interview?
What is BioRestorative Therapies' (BRTX) main business focus?
